Zim Laboratories Ltd

- No plans for deleveraging or increasing borrowings as of now. - CapEx has been largely completed, and future CapEx will be limited to upgrades and technology improvements only. - All major CapEx financed through a mix of internal accruals and borrowings already secured. - No further major projects or large fundraising through debt or equity planned at this moment.

- Major CapEx has already been completed, focusing on upgradation and technology improvement going forward (Page 21, 24). - No further major CapEx or new big projects planned; future CapEx limited to facility upgrades (Page 21, 24). - Capacity utilization currently low; newly built capacity will be better utilized once marketing authorizations (MAs) are received (Page 20, 24). - Strategic focus on expanding geographical footprint and entering regulated markets with NIP and OTF products; investments aligned accordingly (Page 23, 18). - Marketing and sales expansion ongoing, including hiring marketing teams and appointing domestic out-licensing executives (Page 16, 24). - No current plans for deleveraging; financing so far through internal accruals and borrowings with CapEx closed (Page 20, 24).

- The company expects a 25%-30% CAGR growth over the next few years, driven mainly by fast-growing NIP (Novel Innovative Products) and OTF (Orally Thin Film) products. - NIP and OTF currently contribute about 16%-19% of sales, projected to increase to 30%-40% in the coming years, potentially reaching 50% over time. - Growth will come from regulated markets (Europe, Australia, UK) as well as emerging and RoW (Rest of World) markets. - Base/legacy business is expected to stabilize with nominal growth, recovering to past levels after recent challenges. - Revenue increase also depends on successful regulatory approvals, especially in Europe. - Overall top-line growth and EBITDA margin improvement to upper teens are anticipated with better product mix and operational efficiencies.

- ZIM expects a growth rate of 25% to 30% CAGR in revenues over the next few years, driven largely by NIP and OTF products expanding to 30%-40% of total turnover by FY26-FY27. - EBITDA margins are projected to improve to the upper teens (around 15%-17%) as higher-margin NIP/OTF products scale up and operating costs remain rationalized. - FY26 and FY27 are anticipated as inflection points for margin improvement and revenue growth, contingent on regulatory approvals and market launches by end of Q3/Q4 FY26. - Significant CapEx has already been completed; future CapEx will focus only on technology upgrades. - Legacy business stabilizing with nominal growth expected, complementing the high-growth new product lines. - Earnings and margins gains are realistic given rationalized operating expenses, increasing contribution of patented products, and a broader regulated and emerging markets footprint.

- There was a significant order from the Government of Maharashtra worth around INR 20 crores that got deferred due to the election year in FY25. - This order did not get deferred to the next year, impacting the domestic revenue temporarily. - The legacy business faced some delays related to currency issues with a large client, which have now been resolved. - The company expects the legacy business orders to come back to previous levels with nominal growth. - Production schedules for new products depend largely on marketing partners' readiness, with manufacturing expected to start once orders are received. - Regulatory approvals (Marketing Authorizations) are still pending for some markets, especially in Europe, which could affect timelines. - Overall, the company is optimistic about new order inflows starting Q3 FY26 with multiple partners on a nonexclusive basis to mitigate risks.